论文部分内容阅读
目的探讨米非司酮联合肿瘤切除术治疗子宫肌瘤的临床疗效及安全性。方法抽取2013年11月至2015年8月的118例子宫肌瘤患者,根据手术前后是否服用米非司酮分为两组,每组59例。两组均行肿瘤切除术治疗,观察组于手术前3个月及术后3个月均服用米非司酮。对比两组手术前子宫肌瘤大小、住院时间、术后阴道流血时间、月经恢复时间及子宫肌瘤中ER、PR、EGFR的表达、1年内复发率,并对观察组用药安全性进行分析。结果观察组术前子宫肌瘤相比于对照组较小,住院时间、术后阴道流血时间少于对照组,月经恢复时间长于对照组,差异均有统计学意义(P<0.05);观察组肿瘤组织中ER、PR、EGFR阳性率分别为52.54%、25.42%、47.46%,均显著低于对照组的84.75%、76.27%、83.05%,差异有统计学意义(P<0.05);术后1年,观察组复发率为1.69%,显著低于对照组的15.25%,差异有统计学意义(P<0.05);观察组用药期间不良反应发生率为10.17%,未对治疗产生明显影响,且停药后均自行缓解。结论米非司酮联合肿瘤切除术治疗子宫肌瘤,临床效果显著,且安全性较高,值得推广。
Objective To investigate the clinical efficacy and safety of mifepristone combined with tumor resection in the treatment of uterine fibroids. Methods A total of 118 patients with uterine fibroids from November 2013 to August 2015 were selected and divided into two groups according to whether mifepristone was taken before or after operation. Both groups underwent tumor resection. The observation group took mifepristone 3 months before operation and 3 months after operation. The size of uterine fibroids, length of hospital stay, postoperative vaginal bleeding time, menstruation recovery time and the expression of ER, PR and EGFR in uterine fibroids were compared between two groups. The recurrence rate within one year was analyzed. The safety of the observation group was also analyzed. Results The preoperative uterine fibroids in the observation group were lower than those in the control group, the length of hospital stay, postoperative vaginal bleeding time were less than the control group, menstruation recovery time was longer than the control group, the difference was statistically significant (P <0.05) The positive rates of ER, PR and EGFR in tumor tissues were 52.54%, 25.42% and 47.46%, respectively, which were significantly lower than those in control group (84.75%, 76.27%, 83.05%, P <0.05) 1 year, the recurrence rate of observation group was 1.69%, which was significantly lower than that of control group (15.25%), the difference was statistically significant (P <0.05); the incidence of adverse reactions in observation group was 10.17%, which had no significant effect on treatment, After stopping and relieve themselves. Conclusion Mifepristone combined with tumor resection for the treatment of uterine fibroids, clinical effect is significant, and high safety, it is worth promoting.